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ability of spinal cord tissue after injury decreases the potential for repair
and recovery. Initially, in spinal cord injuries (SCI), often the surgeon can
only limit further damage by early surgical decompression. However,
with the development of basic science, especially the development of
genetic engineering, molecular biology, tissue engineering, and materials
science, some promising progress has been made in promoting the
repair of central nervous system injuries. For example, transplantation of
neural stem cells (NSCs), olfactory ensheathing cells (OECs), and genemediated transdifferentiation to repair central nervous system injury.
This paper summarizes the progress and prospects of SCI repair with
tissue engineering scaffold and cell transdifferentiation from an extensive
literatures.

1

Introduction

Spinal cord injury (SCI) is a worldwide medical
problem characterized by severe morbidity, a
high disability rate and high mortality [1–3].
SCI includes primary and sequential spinal cord
injuries, and the main component of the former
is traumatic spinal cord injury after which about
45% of patients will remain paralyzed with a
significantly reduced quality of life [4]. Currently,
there are 2 to 3 million patients with SCI around
the world, a number that is increasing annually
by 130,000, on average. One of the principal
Corresponding author: Yixin Shen, E-mail: 972679925@qq.com

areas of research is to protect the remaining
axons and neurons from secondary damage, and
promote the regeneration of the downlink conduction system, using drugs, stem cells, or other
cell-transplantation techniques. Recently, the
technology of cell transdifferentiation has made
it possible to transform a type of differentiated
cell into nerve cell, which challenges the traditional
idea that the developmental path of terminally
differentiated cells cannot be changed and opens
up new possibilities for the repair of SCI. To
provide some references for basic research and
the clinical treatment of SCI repair, this review
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mainly focuses on the application of tissue engineering scaffolds and cell transdifferentiation.

2 Factors affecting axonal regeneration
after SCI
After SCI, there is a series of traumatic cellular
reactions including astrocyte differentiation into
“scarred” glial cells. These glial cells proliferate
and migrate into the injured area and produce
many important inhibitory factors, including
myelin-associated blockers NI-35, NI-250, myelinassociated glycoprotein (MAG), inhibitory proteoglycan 2, and related toxins, killing damaged
nerve cells, and axons. In addition, acid-base
imbalance, disruption of blood supply, the inactivation of related enzymes and the production
of many inflammatory factors further inhibits
the regeneration of axons in the injured area.
Therefore, the repair of SCI is affected by a variety
of inhibitory factors. In general, among the main
factors affecting axonal regeneration is the ability
to express axon regeneration-related genes. These
control effective trophic factors that promote
axonal regeneration, inhibitory factors that inhibit
axonal growth and elongation, and effective
matrix molecules that guide elongation of axon
regeneration, and isolation from glial scarring.

3

Strategies for promoting axonal
regeneration after SCI

Most scholars recognize that the repair of SCI
should be based on reducing inflammation and
scarring, blocking the influence of inhibitors,
promoting and supporting axonal regeneration,
and encouraging the connection between damaged
axons and target organs. At present, there are
two main strategies for the promotion of axon
regeneration: (1) To change the inhibitory environment of central nervous tissue regeneration.
For example, antibody neutralization reduces the
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formation of inhibitors and scars, and increases
the number of cells that are conducive to axonal
regeneration. (2) To improve the axonal regeneration ability of central nervous cells, including the
application of exogenous nerve growth factors
(NGFs) and neurotrophic factors (NTFs), and
regulation of the expression of related regenerative
genes.

4
4.1

The main researches of SCI repair
Nutrient factors and inhibitory factor
blockers

Reliable experiments have shown that NGFs
and NTFs can promote axon growth and protect
nerve cells from necrosis. Similarly, gangliosides
can stabilize and protect nerve cell function,
activate related enzyme activities, and promote
axonal regeneration. NTF-3 also plays an important role in enhancing synaptic plasticity, promoting neuroprotection and axon regeneration
after SCI [5]. The mRNA sequencing has shown
that the expression of NTF-3 is inadequate in
the injured area after SCI [6]. In a SCI model, the
combination of monoclonal antibody IN-1 with
NTF-3 and brain-derived neurotrophic factor has
been shown to promote axonal regeneration in
the cortical spinal cord. There is much relevant
in-depth research being carried out in this area.
Schwab et al. injected IN-1, a monoclonal
antibody that neutralizes the central nervous
system inhibitor NI-250, into the SCI area and
found that some axons could regenerate up to
10 mm. This suggests that the application of NGFs
could promote axonal growth and improve the
innervation and mobilization of some lower limbs
[7]. In another experiment, IN-1 was injected into
an area of complete corticospinal tract injury, and
it was found that the contralateral corticospinal
tract could flank the spinal cord and cross
the midline, and replace the partially damaged
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corticospinal tract, indicating that monoclonal
antibody IN-1 promotes collateral growth of axons.
Another important inhibitory factor, MAG, has
been discovered, but no corresponding antibody
has been developed. After knocking out the MAG
gene of SCI mice, it has been found that axon
regeneration after corticospinal injury is higher
than that of mice retaining the MAG gene, but
this has not yet translated into the improvement
of motor function. There have been no reports on
the neutralization of proteoglycan so far.
4.2

Tissue engineering scaffold

The characteristics of low survival and nondirectional growth of transplanted cells underlies
the inefficiency of neural structure integration
and reconstruction. With the development of tissue
engineering materials, especially materials with
specific degradation and release characteristics,
this deficiency has been significantly improved.
There are many reports on research into biological
matrix carriers. These include silk fibroin (SF)
scaffolds, fibrin, and hyaluronic acid hydrogels,
bio-protein electrospinning, and prefabricated
shaped scaffolds, especially in combination with
3D printing, to produce biocompatible hybrid
scaffolds. The controlled release of drugs such
as NTF could effectively promote the survival,
proliferation, and differentiation of transplanted
cells in an injured area. Contact-directed or
chemically guided transplanted cells can be made
to grow in a directed and orderly distribution
and we can induce the directional extension of
new nerve fibers, and promote axonal myelination,
and synapse reformation [8, 11, 22, 25].
Hydrogel is a water-rich and porous biomaterial.
The application of hydrogel in an SCI area could
promote local substance exchange, reduce the
damage cavity, promote angiogenesis, contact
and guide cell attachment and growth extension,
and inhibit glial scar formation. Its degradable

characteristics support the production and release
of factors which provide space for the regeneration
of nerve tissue and promote the demyelination
of damaged axons [9, 10]. Boido et al. consider
that the high biocompatibility of chitosan (CS)
based hydrogels guarantees a proper environment for the survival of transplanted cells and
for their ability to provide anti-inflammatory and
antioxidant cues. CS-based hydrogels were developed to host mesenchymal stem cells (MSCs),
thus limiting the formation of glial scarring and
reducing cell death at the injured site. Preliminary in vivo tests on SCI mice revealed good
handling of the CS solution loading MSCs during
implantation, and higher survival rate of the
encapsulated MSCs after 7 days [11]. Dcumens
et al. implanted OECs in a biological matrix
guiding bridge in SCI rats and observed that the
injured corticospinal tract extended significantly
further between the host and graft junction [12].
Cigognini injected RADA16-4GBMHP1 and AcFAQ-LDLK12 hydrogel into SCI rats and found
that both hydrogels can promote hemostasis after
injury, significantly reducing local hematoma
formation. They observed axon regeneration and
obvious recovery of the hind limb movement
and coordination [13]. Ghosh et al. injected
hydrogel-based minocycline hydrochloride (MH)
into the intrathecal space of the injured cervical
spinal cord for local delivery of high concentrations of MH without damaging spinal cord
tissue, and demonstrated that it preserved the
critical phrenic motor circuitry in cervical SCI
models. MH hydrogel also decreased lesion
size and degeneration of cervical motor neuron
somata [14]. After applying QL6 hydrogel to
a rat SCI model, Liu found that QL6 hydrogel
can significantly reduce post-traumatic neuronal
apoptosis, inhibit local inflammation and later
astrocyte activation, and increase axon regeneration
[15]. Studies have shown that hyaluronic acid (HA)
Journal of Neurorestoratology
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can reduce inflammatory cell infiltration and astrocyte proliferation in surrounding tissues after SCI,
and alleviate local inflammation and glial cicatrix.
The neurotrophin-modified HA-methylcellulose
hydrogel, which can achieve sustained release of
supporting factors in the specific location, was
implanted into the SCI area of rats and it was able
to reduce scar formation, and promote axonal
extension across the damaged area. In the region,
HA-methylcellulose-NTF3 also inhibited the proliferation of astrocytes, the inflammatory response,
and significantly alleviated syringomyelia after
SCI. Li et al. implanted an NTF3-SF scaffold
into an SCI canine model, which significantly
inhibited glial scars, narrowed the lesion cavity,
and improved the hindlimb motor function and
nerve conduction in the experimental dogs [5].
Ranch et al. combined vascular endothelial cells
(ECs) with NSCs in a hydrogel implant and
found that this composite scaffold could induce
angiogenesis in a rat SCI model [16]. Arulmoli
found that hydrogel materials such as fibrin and
HA have an angiogenic effect [17] and in in vitro
3D culture, HA has shown the ability to induce
ECs to form capillary structures [18] and this
vascularization is associated with cell adhesion
and migration. Collagen can inhibit endothelial
cell tube formation when added to a fibrin matrix
in vitro [19]. In another rat model, after implanting collagen matrix with VEGF, angiogenesis and
recovery of neurological function were observed.
Chedly et al. designed a scaffold material for
SCI treatment containing only CS and water
as fragmented physical hydrogel suspension
(Chitosan-FPHS), with a defined degree of
acetylation, polymer concentration, and mean
fragment size. It is found to promote reconstitution
of spinal tissue and vasculature. Growing axons
were myelinated or ensheathed by endogenous
Schwann cells, whose survival was prolonged,
that migrated into the lesion site [20]. Prefabricated
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shaped scaffolds are mainly suitable for severely
damaged or semi-transverse injury models. Their
advantages are stable mechanical structure, slower
degradation than hydrogel, and longer structural
support and drug release. The pore ratio and
modification of its chemical composition can be
precisely regulated, providing mechanical support
for cell transplantation, axonal regeneration and
reconstruction of synapses, as well as chemical
orientation information [21]. In another experiment by Zeng et al., induced pluripotent stem
cells (iPS cells) were transplanted into threedimensional gelatin prefabricated scaffold wrapped
with polylactic-co-glycolic acid copolymer, and
implanted into the injured spinal cord. The cell
scaffold was found to reduce inflammation at the
injury site, motivate angiogenesis, support longterm survival of transplanted cells, promote axonal
regeneration, and extend along the scaffold morphology [22]. Jalali Monfared et al. used MiR-219
overexpressed human endometrial stem cell-derived
oligodendrocyte progenitor cells encapsulated
in fibrin hydrogel, as an injectable scaffold.
After it was injected to the injury site, the rate
of myelination was observed to be significantly
higher, but it did not cause recovery of motor
function [23]. Duan et al. added the transplanted
cells and NTF to a prefabricated degradable
scaffold and placed it in the injured spinal
cord region. After the scaffold degradation, the
regenerated axons were seen passing through the
damaged area and were distributed in an ordered
longitudinal structure [24]. Nowadays, the strategy
of combining tissue engineering materials with
cell transplantation to repair nerve injury is
becoming a viable research field.
4.3

Gene therapy

The regenerative capacity of the central nervous
system gradually reduces with age, mainly due
to decreased expression of nerve growth-related
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genes [25, 26]. Micro RNA (miRNA ), as a key
molecule regulating cell biological processes, plays
a key role in the nervous system by regulating
neuronal internal signaling pathways. miRNA
could be widely used as a diagnostic and
therapeutic target in clinical and basic research
[27]. miRNA-signal transducer and activator
of transcription 3 (STAT3) signaling pathway
is involved in the complex molecular biological
process such as differentiation of nerve cells,
maturation, and release of neural mediators [28,
29]. STAT 3 as an upstream transcription factor,
promotes the expression of growth-associated
protein 43 (GAP43) in neurons, thereby promoting
regeneration of axons [30–32]. Up-regulation of
miRNA-21 expression is associated with prolonged
cell survival, promotes cell growth, proliferation,
and reduces apoptosis. Hu et al. used miRNA-21
antagonists to inhibit the expression of miRNA-21
in neurons, resulting in decreased recovery of
hindlimb motor function in SCI rats, increased
range of lesions and decreased normal tissue
range. Compared to the negative control group,
miRNA-21 antagonists significantly increased
apoptosis [33]. The proapoptotic genes fas ligand
(FasL), phosphatase and tensin homolog (PTEN)
and programmed cell death protein 4 (PDCD4)
have been shown to be the direct target of
miRNA-21. And miRNA-21 antagonist could
increase the expression of FasL and PTEN in vivo
but does not affect the expression of PDCD4,
indicating that miRNA-21 can attenuate the
occurrence of secondary apoptosis after SCI, which
may be related to the regulation of apoptosispromoting genes [34]. Bhalala et al. overexpressed
miRNA-21 in transgenic mouse astrocytes, and
the results show that the overexpression reduces
secondary apoptosis after SCI and increases the
axonal density in the damaged area [35]. Song et
al. transplanted miR-124-modified bone marrow
mesenchymal stem cells (BMSCs) into SCI rats

and found that overexpression of miRNA-124
inhibited the expression of pyridoxal kinase
(PDXK) and accelerated the differentiation of
BMSCs into neural cells [36]. Dergham validated
that the reduced expression of RhoA by miRNA133-b could promote the repair of the corticospinal
tract [37]. Conrad et al. found that miRNA-133-b
expression was significantly up-regulated in the
adult zebrafish SCI model, and further, inhibition
of RhoA promoted repair of the corticospinal tract
[38]. Jee et al. infused miRNA486 into the spinal
cord of healthy mice and found the expression
of neurogenic differentiation 6 (NeuroD6) was
significantly inhibited. The motor function of the
mice decreased and neuronal death increased.
In contrast, knocking out miRNA486 revealed
enhanced expression of NeuroD6 and improved
recovery of hind limb function in the mice [39].
NeuroD6 is an important protein for neuronal
differentiation and oxidative stress. As a target,
it could inhibit miRNA486 by up-regulating
NeuroD6 expression, thereby reducing apoptosis
and improving functional recovery after SCI.
Currently, miRNA-21, miRNA-l24, miRNA-219,
miRNA-338, miRNA-133-b, miRNA-486, and
miR-20a-3p are known to target STAT3, thereby
regulating the extension ability and regeneration
of neuronal axons after SCI.
4.4

Cell transdifferentiation

In 2002, Tosh et al. defined transdifferentiation
as the process by which a differentiated cell is
irreversibly transformed into another differentiated
cell [40], i.e., the gene of one somatic cell is directly
reprogrammed into another cell type without
transition into a cell pluripotency state [41]. Wada
et al. converted fibroblasts expressing the single
transcription factor MyoD into myoblasts for
the first time [42]. To date, many studies have
reported that a somatic cell can be transdifferentiated to another functional cell [43–46]. Methods
Journal of Neurorestoratology
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for transdifferentiating cells into neurons include
the inducible neurons (iNs) technique, induced
pluripotent stem cells (iPSCs) technique and
indirect lineage conversion (ILC) technique.
To obtain the neural cells, iPSCs technique
involves directly reprogramming genes to obtain
induced neural stem cells (iNSCs) or induced
neural progenitor cells (iNPCs). But iPSCs
technology has low induction efficiency, poor
proliferation ability, and unstable epigenetic and
biological characteristics, which greatly increase
the degree of degeneration or malignancy of cells.
The iNs technique directly reprogrammes a gene
to transdifferentiate cells to iNs without intermediate steps such as the creation of pluripotent
stem cells [47]. iNs has a corresponding physiological function. Liu et al. injected the transcription factor ASCL1 into the dorsal midbrain
of mice by the adeno-associated virus carrier with
GFAP and found AST is transdifferentiated into
functional neurons [48]. Bonilla transdifferentiated
human MSCs into neurospheres and neuron-like
cells within 3 to 7 days [49]. However, this method
can only be applied to the transformation of
certain lineage cells, and the efficiency is still
very low, which limits cell proliferation making
it difficult to obtain enough cells for clinical use.
Since the emergence of iPSCs and iNs techniques,
they have been used to transdifferentiate cells
into blood cells, hepatocytes, cardiomyocytes and
nerve cells [46, 50].
ILC is a technique in which differentiated
cells are dedifferentiated and lose their initial
phenotype, allowing cells to exhibit a plastic
transitional state and finally induce differentiation
into new types of cells. For the first time, Kurian
et al. used the ILC method to transdifferentiate
human fibroblasts into progenitor vascular cells
[51]. These new cells not only proliferate but also
differentiate into ECs and vascular smooth muscle
cells. Lim et al. used the co-expression of myelin
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transcription factor 1 (Myt 1) and the inhibitor
of apoptosis gene Bcl-xL to transdifferentiate
fibroblasts into iNPCs with better proliferative
capacity, and then added nuclear receptor-related
factor (Nurr) of dopamine-associated transcription
factor and forkhead box protein A2 (FoXA2),
which is beneficial to neuronal growth. The result
was iNPCs being converted into neurons with
dopaminergic neurological function [52]. Subsequently, Doeser et al. induced the protooncogene
OSKM from the skin wound of transgenic mice to
transdifferentiate fibroblasts into myofibroblasts,
thereby improving tissue healing, reducing scar
tissue, and reducing the risk of tumor [53].
Compared with iPSCs or iNs technology, ILC
is a simple and effective technology, which can
rapidly generate stem cells, and has cross-line
differentiation potential. It shortens the operation
time and reduces the risk of tumorigenesis.
Therefore, it is a promising candidate to meet
the needs of clinical application in the future with
regard to both cell types and required quantities.
Astrocytes (AST) are rapidly activated to form
reactive astrocytes after central nerve injury. This
process is called “AST activation”. RAS undergoes
defensive changes of AST in morphology, gene
expression, proliferation, and function to deal
with the complex pathology after central nerve
injury including SCI [54]. The activation of AST
may be related to the expression of the telomerase
reverse transcriptase gene. In the early stage of
SCI, RAS can inhibit the spread of inflammation,
reduce the extent of injury, and promote the
repair of wound sites. In the advanced stage,
hyperproliferative RAS can form glial scars at the
injury site [55], which blocks the regeneration
of axons, can also secrete axonal regeneration
inhibitory factors. Experiments have shown that
nestin, a specific marker of many NSCs, can be
seen in the injured central nervous system.
Although NSCs proliferate, they have not yet
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successfully differentiated into neurons. It has
been confirmed that matrix metalloproteinases
(MMPs) can be released in RAS by Falo et al.
MMP-3 repairs damaged extracellular matrix
proteins and helps them to degrade the debris
of cell necrosis, establishing a microenvironment
that is beneficial for axonal regeneration [56]. As
an endogenous repair mechanism, RAS can use
the relevant NTFs to provide a material basis for
limited axonal regeneration [57–58], however, the
numbers of regenerated axons cannot completely
replace the damaged neurons. Therefore, RAS is
directly transdifferentiated into neurons in vivo,
replacing the destroyed neurons and integrating
those remaining into the neural network. In
addition, glial scars can be suppressed, thereby
removing the blocking effect on axonal extension.
So far, scholars have tried to use transcription
factors, signal pathways and other methods to
stimulate transdifferentiation. Faiz et al. transdifferentiated RAS into neurons by the forced
expression of ASCL1 in the subventricular region
of the mouse [59]. Guo et al. injected Neuro D1
into the mouse striatum using a retrovirus and
found that overexpression of Neuro D1 can
directly reprogram RAS into functional neurons
in the mouse cortex in vivo [60]. Magnusson
demonstrated that blocking Notch signaling can
trigger AST to transdifferentiate into neurons in
the striatum of normal mice. Therefore, AST can
be transdifferentiated into nerve cells under the
regulation of Notch signal [61]. RAS was transdifferentiated into pluripotent neurospheres by
Sirko et al. via the SHH signaling pathway [62],
and Shen et al. demonstrated that VEGF participates in the process of AST transdifferentiation
into nerve cells in the striatum [45]. Therefore,
the RAS can be stimulated to differentiate into
nerve cells by activating relevant signaling pathways, and the spinal neural network may be
reconstructed after SCI.

At present, the studies on cell morphological
and functional integrity, epigenetic changes,
genetic integrity, telomere and telomere, cell
memory and immunogenicity are relatively simple.
There are few studies on the transdifferentiation
of RAS into neurons. The complex microenvironment in vivo is still challenging to the current
transdifferentiation technology. Although the
transdifferentiation techniques are not yet mature
enough, they are challenging the traditional idea
that the developmental path of terminally differentiated cells cannot be changed, and opening up
a promising new future for the repair of SCI.

7

Summary

There are reports of repair methods such as
peripheral nerve transplantation and pulse electrical stimulation. However, due to the limited
ability of the central nervous system to regenerate
and the intricate pathological changes after SCI,
a single treatment method will not be adequate.
The “combination” of several methods may greatly
improve our ability to repair SCI. Cao et al. firstly
implanted the glial cell line-derived neurotrophic
factor (GDNF) gene into OECs using a retroviral
vector, and found that GDNF gene-modified OECs
not only expressed and secreted biologically active
GDNF in vitro but also continuously produced
GDNF in vivo, which significantly promoted
axonal regeneration and functional recovery in
complete injury of T10 spinal cord in rats. It
increased the Basso Beattie Bresnahan (BBB) scale
score of the hind limb function from 4 to 9 [63].
Fouad et al. transplanted a chondroitinase preformed scaffold containing OECs into a complete
SCI rat and observed the regeneration of axons
extending along the scaffold and obvious recovery
of motor function [64]. Therefore, a “combined”
approach such as transdifferentiated cells combined with tissue engineering materials will
become an important field of research.
Journal of Neurorestoratology
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